Quarterly ResultAug 5, 2026, 04:30 PM
Coherus Q2 Net Loss $(33.3)M, LOQTORZI Revenue $13.6M
AI Summary
Coherus Oncology reported Q2 2026 financial results, with LOQTORZI net revenue reaching $13.6 million, a 37% increase year-over-year. The company significantly reduced its net loss from continuing operations to $(33.3) million, or $(0.22) per diluted share, compared to $(44.9) million in the prior year. Coherus also highlighted strong commercial performance for LOQTORZI and continued advancement of its oncology pipeline, with initial data readouts for Tagmokitug and Casdozokitug expected in the second half of 2026.
Key Highlights
- LOQTORZI net revenue was $13.6 million in Q2 2026, up 37% YoY.
- Net revenue from continuing operations reached $14.3 million in Q2 2026.
- Net loss from continuing operations was $(33.3) million in Q2 2026.
- Diluted EPS from continuing operations was $(0.22) in Q2 2026.
- R&D expenses decreased to $21.4 million in Q2 2026.
- SG&A expenses decreased to $21.0 million in Q2 2026.
- Cash, cash equivalents, and marketable securities totaled $105.3 million.
- Initial data readouts for Tagmokitug and Casdozokitug expected 2H 2026.
Price Impact
More from CHRS